

1 **Title Page**

2 Genomic and epigenomic evolution of metastatic prostate cancer: the first warm
3 autopsy in China

4

5 Wenhui Zhang^{1†}, Yan Wang^{1†}, Min Qu^{1†}, Haoqing Shi^{1†}, Xin Lu¹, Qingsong Yang²,
6 Fang Liu², Tao Wang³, Ziwei Wang¹, Bijun Lian⁴, Ling Chen⁵, Xiaoyi Yin⁶, Yongwei
7 Yu⁷, Jing Li^{8,9,a*}, Xu Gao^{1,b*}, Zhuan Liao^{10,c*}

8

9 ¹ Department of Urology, Changhai Hospital, Second Military Medical University,
10 Shanghai 200433, China

11 ² Department of Radiology, Changhai Hospital, Second Military Medical University,
12 Shanghai 200433, China

13 ³ Department of Urology, the First Affiliated Hospital of Zhengzhou University,
14 Zhengzhou, Henan 450052, China

15 ⁴ Department of Urology, the 903rd PLA Hospital, Hangzhou, Zhejiang 310012,
16 China

17 ⁵ Department of Oncology, Changhai Hospital, Second Military Medical University,
18 Shanghai 200433, China

19 ⁶ Department of Hepatobiliary Pancreatic Surgery, Changhai Hospital, Second
20 Military Medical University, Shanghai 200433, China

21 ⁷ Department of Pathology, Changhai Hospital, Second Military Medical University,

22 Shanghai 200433, China

23 ⁸ Shanghai Key Laboratory of Cell Engineering, Second Military Medical University,

24 Shanghai 200433, China

25 ⁹ Department of Bioinformatics, Center for Translational Medicine, Second Military

26 Medical University, Shanghai 200433, China

27 ¹⁰ Clinical Research Center, Changhai Hospital, Second Military Medical University,

28 Shanghai 200433, China

29

30 † These authors contributed equally to this work.

31 * Corresponding author.

32 a Department of Bioinformatics, Center for Translational Medicine, Second Military

33 Medical University, Shanghai 200433, China. Tel.+86 15801 966205; Fax: +86 21

34 8187 0033; E-mail address: ljing@smmu.edu.cn

35 b Department of Urology, Changhai Hospital, Second Military Medical University,

36 Shanghai 200433, China. Tel.+86 13501 655091; Fax: +86 21 3503 0006; E-mail

37 address: gaoxu.changhai@foxmail.com.

38 c Clinical Research Center, Changhai Hospital, Second Military Medical University,

39 Shanghai 200433, China. Tel.+86 13061 921980; Fax: +86 21 3116 1004; E-mail

40 address: zhuanleo@126.com.

41

42 **Abstract**

43 **Background:** The development and expansion of warm autopsy program have
44 important implications in dissecting the heterogeneity during cancer dissemination
45 and resistance. However, in China, the practice of warm autopsy has not yet been
46 officially launched and documented.

47 **Methods:** To explore and establish the procedures and standards for warm
48 autopsy in China, we followed the disease course of a male patient with terminal
49 metastatic prostate cancer. We assembled a multidisciplinary team to perform
50 warm autopsy immediately after death. Through longitudinal sampling from biopsy
51 and autopsy, we performed integrative and comprehensive genomic and
52 epigenomic analysis using multi-omics approaches.

53 **Results:** We traced the dynamic evolution and heterogeneity of this prostate
54 tumor, and identified many critical driver events in both the original tumor and its
55 disseminations. Truncated *CDKN1B* may result in downregulation of expression,
56 which represent a key driver event in the metastatic progression of prostate cancer.
57 We also delineated the congruence of genetic and epigenetic clonal evolution
58 during tumor metastasis.

59 **Conclusions:** Our data and analysis elucidated the mechanisms and drivers
60 during metastasis, which represent a valuable resource for the study and
61 treatment of prostate cancer. We also call on more investigators to improve warm
62 autopsy of prostate cancer for clinical and experimental investigations.

63 **Keywords:** Clonal evolution; Intratumor heterogeneity; Prostate cancer;
64 Metastasis; Epigenetics.

65

66 **Background**

67 Prostate cancer is the one of the most common malignancies of men in China, and
68 the incidence and mortality rates are much higher than the average levels
69 worldwide¹. The majority of prostate cancer deaths are attributed to metastatic
70 dissemination of the primary tumor^{2,3}. The collection and investigation of tumor
71 samples at multiple metastatic sites can be instrumental in dissecting the evolving
72 complexity of tumor metastasis. The needle biopsy is not practical for
73 simultaneously acquiring metastatic tumors from multiple sites of the same patient.
74 In contrast, multiple tissue harvesting by autopsy is an excellent way to collect
75 most tissues and preserve most viable samples.

76 The Autopsy Section investigates final diagnosis of the disease which caused the
77 death of a patient in clinic. In academic settings, autopsies provide an opportunity
78 for researchers and students to understand disease process by studying
79 postmortem tissues and the clinical record. An important function of an academic
80 autopsy service is to process tissues for research purposes. The advent of
81 “immediate” autopsy in 1976 enabled acquisition of inaccessible tissues and cells
82 for culturing⁴. The prototype of “warm autopsy” at an academic institution was
83 developed in the 1980s⁵. After the stable and integrated infrastructure setting up

84 for cells isolation, the purpose for rapid autopsy had been shifted to specimen
85 biobanking⁶. In 2000, “warm autopsy” as a term has been defined as acquisition of
86 tissue samples through immediate autopsy shortly after death⁷. A team at
87 University of Michigan successfully collected 8 different tissue types from 14 warm
88 autopsy cases within 4 years, meeting the need of collecting high-quality primary
89 and metastatic tumor samples for molecular studies.

90 Today, with the advent of next-generation sequencing, warm autopsy represents
91 the next phase in modern pathology. Warm autopsy program has now been
92 implemented in many countries⁸⁻¹⁰. However, the study of warm autopsy has
93 lagged behind in China. There is no documented program for this specific research
94 area in China to-date.

95 Here, we report the first, to our knowledge, warm autopsy in China. By performing
96 sequencing on eight metastatic tissues collected via warm autopsy from an
97 advanced prostate cancer patient, we revealed extensive intratumor heterogeneity
98 between different metastases, and delineated the congruence of genetic and
99 epigenetic clonal evolution. Our work developed the procedures and standards for
100 warm autopsy, and we call on Chinese urologists and oncologists to promote warm
101 autopsy of prostate cancer for clinical and experimental investigations.

102 **Methods**

103 **Patient information and course of the disease**

104 A male patient in his 60s was diagnosed with prostate adenocarcinoma in January
105 2016. The transrectal ultrasound-guided prostate biopsy showed prostate cancer
106 (T3aN1Mx, tPSA: 20.166 ng/ml, Gleason Score: 5+5). The patient was started on
107 treatment with ADT and chemotherapy, after a short partial response (PSA
108 2.52ng/ml). Soon after the patient got into mCRPC. Left clavicle lymph node and
109 multiple vertebral metastases were detected by MRI in July 2016. Then the ADT
110 and chemotherapy were suspended, and collection of plasma and lymph node (LN)
111 biopsy was initiated for further treatment evaluation. Two months later, treatment
112 was switched to Vemurafenib due to a *BRAF* V600E mutation detected by the
113 ctDNA targeted sequencing. General deterioration then occurred, with disease
114 progression into cachexia (dyspnea, renal insufficiency and heart failure).
115 Treatment was stopped and the patient died on January 2017. Tumor samples for
116 sequencing were obtained from the primary prostate sites at diagnosis and
117 metastases at warm autopsy.

118 **Committee establishment**

119 With the support of the Changhai Warm Autopsy Team (CWAT) and Red Cross,
120 the committee of warm autopsy was established, which consisted of a clinical care
121 team (including urologists and oncologists), surgeons (including general surgeons,
122 orthopedists, cardiothoracic surgeons, and neurosurgeons), pathologists,
123 researchers (including translational medicine center and laboratory assistants),
124 ethics board and the administrative unit (Fig 1). Patients diagnosed with end-stage

125 CRPC were referred to the Urology Department of Shanghai Changhai Hospital.
126 The objectives and procedures for this study were explained to the patient carefully.
127 Permission for warm autopsy was obtained before the death, with consent
128 provided by the patient and the family members. After death, consent was
129 obtained by the family members with the witness by the operator and the ethics
130 committee. Written informed consent was obtained in accordance with Chinese
131 legislation. Sample collection and study were approved by the ethical board at
132 Changhai Hospital (No: TMEC2014-001, No: CHEC2019-165).

133 **Implementation of the warm autopsy**

134 The body was sprayed with ethanol before operation. Then the operator
135 approached the internal organs through an “+ shaped” incision, up to the
136 collarbone, down to the pelvis, extend the middle route on both sides. The skin and
137 subcutaneous tissues were retracted from the thorax and abdomen, and the blood
138 and other body fluid were collected in the tubes. Around the warm autopsy
139 operator, there were 6 independent collection areas for tissue procurement and
140 storage (Neurosurgery, Cardiothoracic, Urology, General Surgery, Orthopedic,
141 and Pathology biobank). Firstly, the urological operator resected the prostate,
142 urinary bladder, and pelvic lymph nodes in a manner similar to that of a
143 cystoprostatectomy. Then the kidneys, adrenal glands and ureters were resected
144 in a manner similar to that of a nephroureterectomy. Secondly, the breastplate was
145 removed by cardiothoracic surgeon. The heart, lungs, aorta and mediastinum were

146 resected orderly. Meanwhile, the general surgeon reseed the stomach, liver,
147 gallbladder, pancreas, colon and retroperitoneal lymph nodes. Thirdly, the
148 orthopedist collected the bone metastases as well as the control tissues, and the
149 neurosurgeon collected the brain. The tissue was cut into approximately
150 10mm×10mm×20mm slice, which was divided into three contiguous aliquots for
151 the homology of purified DNA/RNA/protein. And we do triplication repeat to
152 guarantee the quality of tissue. Finally, tumor tissues from eight metastatic sites
153 and normal tissues from 23 anatomic sites were procured by warm autopsy. The
154 collection of normal tissues referenced the Genotype-Tissue Expression (GTEx)
155 project¹¹, included kidney (cortex), ureter, bladder, testis, adrenal gland, brain
156 (cortex), brain (cerebellum), bone, heart (left ventricle), artery, breast, thyroid,
157 esophagus (muscularis), stomach, pancreas, omentum, gallbladder, liver, colon,
158 ileum, jejunum, muscle, skin (suprapubic).

159 **Pathological evaluation of specimens and tissue storage**

160 All autopsy samples were immediately frozen in liquid nitrogen and stored at
161 –80 °C. One primary sample (PB2) and seven fresh-frozen samples from warm
162 autopsy except for bone (LV2M) were also stored in RNAlater (Ambion) for RNA
163 extraction according to manufacturer protocol ([Supplementary Table S1](#)).
164 Hematoxylin and eosin (H&E) stains were performed for thin slices of snap-frozen,
165 OCT-embedded tissue blocks using standard techniques. Tumor staging and
166 pathological grading were independently determined by two professional

167 uropathologists. Bone metastases were defined using emission computed
168 tomography (ECT). According to EAU guidelines, the diagnostic criteria for CRPC
169 were the castrate levels of serum testosterone < 50 ng/dL, or 1.7 nmol/L plus one
170 of the biochemical progression or radiological progression¹².

171 **Somatic mutations calling**

172 Somatic mutations including single nucleotide variants (SNVs) and small-scale
173 insertions/deletions (Indels) were detected using Mutect2 from GATK v4.0.11.0
174 and Strelka2 v2.8.2¹³. The annotation of the somatic mutations was performed with
175 the ANNOVAR tool¹⁴. In addition, we used the panel of normals (PoNs) built from
176 the 208 normal samples in the previous study¹⁵ to remove and filter the recurrent
177 technical artifacts that mutations appeared in more than one PoN samples. We
178 removed mutations with minor allele frequency > 5% in the NHLBI GO Exome
179 Sequencing Project (<http://esp.gs.washington.edu>), the 1000 Genomes cohort
180 (<http://www.internationalgenome.org>), and the ExAC resource
181 (<http://exac.broadinstitute.org>), but retained all COSMIC variants. Mutations within
182 the blacklist that we compiled according to the MutSigCV paper were also filtered
183 and removed¹⁶. Additionally, we also removed variants in repetitive elements
184 (RepeatMasker <http://www.repeatmasker.org/>) or segmental duplications (UCSC
185 hg19.genomicSuperDups). Finally, the candidate mutations in previously
186 implicated cancer genes were reviewed manually on the Integrated Genomics
187 Viewer (IGV) to ensure that no candidate driver mutations were mistakenly

188 removed. The correct nomenclature for mutation was checked applying
189 Mutalyzer¹⁷.

190 **Somatic copy number alterations calling**

191 We utilized the FACETS v0.5.6 algorithm¹⁸ to detect somatic allele-specific copy
192 number alterations (CNA) and determine the tumor purity of the tumor samples
193 from WGS data. The copy number alteration events were defined to meet the
194 following criteria as previously described¹⁹: (1) regions with total copy number =
195 3-8 were defined as a gain event; (2) total copy number > 8 were defined as an
196 amplification event; (3) regions with total copy number = 1 were defined as a loss
197 event, and (4) total copy number = 0 were defined as a homozygous deletion event.
198 Additionally, regions with minor copy number = 0 and total copy number > 0 will be
199 defined as a loss of heterozygosity (LOH) event, including LOH (or loss, total copy
200 number = 1), CN-LOH (Copy neutral loss of heterozygosity, total copy number = 2)
201 and Gain-LOH (Copy gain loss of heterozygosity, total copy number > 2).

202 **Genetic clone evolution analysis and driver events annotating**

203 PyClone²⁰, an algorithm to infer clonality by the Bayesian clustering method, was
204 conducted to reconstruct the accurate clonal and subclonal architecture across
205 primary and metastatic tumors. The somatic mutations with depth higher than 30x
206 for WGS and 100X for WES were used as input to PyClone. Using the
207 Bam-readcount v0.8.0 (<https://github.com/genome/bam-readcount>) with minimum
208 base quality 20, we calculated the reference and alternate read-depth of each

209 mutation from the BAM files. To infer cancer cell fraction (CCF) and cluster
210 mutations, PyClone beta-binomial model with the “parental_copy_number” and
211 “--tumor_contents” option was run for 50,000 iterations. Clusters containing two or
212 fewer variants were discarded. Mutations clusters identified were imported into
213 ClonEvol²¹ to track and visualize tumor’s clonal evolution ([Supplementary Table](#)
214 [S2](#)). The potential driver events for somatic mutations and CNA were annotated as
215 described previously¹⁹. Driver gene mutations were labeled in clonal evolution
216 trees according to the results of ClonEvol, and the driver CNA events were labeled
217 by matching the presence/absence status of the copy number events with that of
218 the clusters across samples. The body map was drawn by referring the study of
219 Gunes Gundem et al²².

220 **Analysis for Intratumor heterogeneity of DNA methylation**

221 Methylation calls and differentially methylated cytosines were analyzed using R
222 package methylKit v1.2.0²³. No batch effects were identified by assocComp in
223 methylKit and there were no plating issues. The top 1% of CpG sites (n=150,000)
224 with the greatest intratumoral methylation range were selected for downstream
225 analysis. Clustered heatmaps were drawn using the superheat package
226 (<https://github.com/rlbarter/superheat>), and Euclidean distance was calculated for
227 hierarchical clustering. We calculated the DNA methylation variability²⁴, which was
228 defined by the median of the range of CpG sites, to measure the intratumoral
229 heterogeneity of methylation in genomic contexts. The higher the methylation

230 variability represents the more ITH observed. The CpG annotation reference was
231 obtained from the R package annotatr (<https://github.com/hhabra/annotatr>).
232 Methylation levels at least 20% increase/decrease relative to the average of
233 normal samples were defined as hyper- methylation and hypo-methylation,
234 respectively.

235 **Reconstruction of methylation and mutation-derived phylogenetic tree**

236 We performed the dist function in the R to generate DNA methylation Euclidean
237 distance matrices using the top 1% of CpG sites with the greatest intratumoral
238 methylation range. The mutation Euclidean distance matrices were calculated
239 using the CCF or VAF of mutations that were input to ClonEvol, and the mutations
240 private to PB2 and LV2M were removed. The fastme.bal function in the R package
241 ape²⁵ was used to reconstruct the Euclidean distance matrices-based phylogenetic
242 tree by applying the minimal evolution algorithm. Confidence for the branches on
243 phylogenetic trees was assessed by bootstrapping (1,000 bootstrap replicates)
244 using the boot.phylo function in the R package ape. Congruence between the
245 genetic and epigenetic distance matrices was calculated by the Spearman's
246 correlation coefficient.

247 More detailed methods are provided in Supplementary Materials and Methods.

248 **Results**

249 **Program development: the warm autopsy in China**

250 To gain insight into the intratumor heterogeneity and evolutionary mechanisms
251 during tumor metastasis and drug resistance, we established the Changhai Warm
252 Autopsy Team (CWAT), a multidisciplinary team, to recruit cancer patients close to
253 the end of life and perform warm autopsies for tumor sampling in disseminated
254 disease (Fig 1). The team was consisted of urologists, general surgeons,
255 orthopedists, cardiothoracic surgeons and neurosurgeons for harvesting all normal
256 and cancer tissues; blood bank technicians for blood collection; additional
257 members responsible for tissue processing and labeling; pathologists for
258 pathology review and translation medicine center personnel for research and data
259 analysis. All team members were permanent employees and were available
260 round-the-clock. The warm autopsy committee approved the protocol, procedures,
261 and methods for obtaining informed consent. In Fig 1 we diagramed the warm
262 autopsy operation station, which contained 6 independent collection areas for the
263 tissue procurement and storage. The unique identifier of each sample was
264 assigned during autopsy. All clinicopathologic information related to the patient's
265 medical and surgical history, medications, imaging studies, pathology and autopsy
266 findings were deposited in a follow-up database PC-FollowTM26.

267 **Patient information and tissue collection**

268 The subject was diagnosed with prostate adenocarcinoma, and received androgen
269 deprivation therapy (ADT) combined with systemic chemotherapy right after
270 primary diagnosis (Fig 2A). However, an elevated prostate specific antigen (PSA)

271 level and multiple metastases detected by imaging indicated disease progression
272 to metastatic castration-resistant prostate cancer (mCRPC) in July 2016. To assess
273 tumor progression, ADT combining chemotherapy was discontinued, and the
274 metastasis was found at left supraclavicular and right pelvic lymph nodes by
275 ultrasound-guided needle biopsy. Targeted sequencing was performed in plasma
276 samples using a custom gene panel for ctDNA (circulating tumor DNA), and
277 Vemurafenib therapy was applied based on the discovery of the *BRAF* V600E
278 mutation. The allele fraction (AF) of *BRAF* mutation decreased during targeted
279 therapy ([Supplementary Fig 1](#)). After a slight improvement in the patient's condition,
280 dyspnea and renal insufficiency began to appear in December 2016. Despite
281 systematic support, the patient succumbed to multiple organ failure in January
282 2017. After death, the tumor tissues from eight metastatic sites and normal tissues
283 from 23 anatomic sites were procured and stored by warm autopsy ([Fig 2B](#)). The
284 autopsy was completed in a total of 2.5 hours, and performed as outlined in
285 "Methods".

286 In this patient, the autopsy revealed widely disseminated prostate tumors in
287 bladder, peritoneum, seminal vesicles, lymph nodes and bones ([Fig 2B](#),
288 [Supplementary Fig 2A](#)). Among them, we observed that the chains of lymph nodes
289 were involved by metastatic spread, and the retroperitoneal and supraclavicular
290 lymph nodes were two obvious sites of metastasis. Additionally, we identified
291 additional metastases through autopsy and pathological review; however, due to

292 the limited sample size and ethical considerations, we did not retain them for
293 further analysis ([Supplementary Fig 2B](#)). In addition to common metastatic sites of
294 prostate cancer such as the adrenal gland and liver^{27,28}, we also identified the
295 metastatic cancer thrombus in quadriceps femoris muscle and inferior vena cava,
296 and skin metastases ([Supplementary Fig 2B](#)). These rare and atypical metastatic
297 foci highlight the complexity of prostate cancer dissemination.

298 To determine the genetic and epigenetic heterogeneity and metastatic progression
299 of cancer that gave rise to the lethal tumor burden, high quality tumor samples
300 collected across different clinical courses were profiled using multi-omics
301 approaches including whole genome sequencing (WGS), whole-exome
302 sequencing (WES), whole-genome bisulfite sequencing (WGBS) and RNA
303 sequencing (RNA-seq) ([Fig 2C, D](#)). In total, 11 tumor samples and one
304 non-cancerous matched healthy prostate tissue were collected for sequencing.
305 The tumor samples included three treatment naïve tumor specimens were
306 obtained from prostate FFPE biopsy, and eight metastases from warm autopsy
307 ([Fig 2D](#)). To describe the heterogeneity of primary tumor, we performed WGS on
308 four prostate samples. Limited by the small size of the puncture tissue, however,
309 we only selected an adequate sample (PB2) for additional WES and RNA-seq. For
310 seven metastases samples, we performed WGS, WES, WGBS and RNA-seq to
311 dissect the evolutionary progression, while bone samples (LV2M) only performed
312 WGS due to the small sample size ([Supplementary Table S1](#)).

313 **Intratumoral genetic heterogeneity of prostate primary tumors**

314 To characterize the genetic origin and subclonal architecture of primary tumors,
315 we analyzed WGS data of three biopsy samples at the time of initial diagnosis (Fig
316 2C). Due to the relatively low tumor purity (34%) of sample PB2 estimated by WGS,
317 we further performed ultra-deep WES (1,119X) on this sample. All 3
318 treatment-naïve tumors shared widespread somatic mutations, including *TP53*
319 p.(Asn179Glnfs*26) and *CDK12* p.(Ala993Val) (Fig 3A) that have been
320 demonstrated to be frequently mutated in previously characterized metastatic
321 prostate cancer cohorts^{29,30}. To determine the clonality of somatic mutations, we
322 further calculated the AF distributions (Fig 3B). Remarkably, the *TP53* and *CDK12*
323 mutations had the largest allele frequencies which matched each tumor sample's
324 purity, suggesting that these mutations are clonal and present in almost all tumor
325 cells. Copy number alteration (CNA) analysis revealed that all three samples
326 underwent loss of heterozygosity (LOH) of *TP53* and *CDK12*, resulting in complete
327 inactivation of these known prostate cancer genes (Fig 3C). Utilizing the somatic
328 mutations as a molecular clock as described previously³¹, we explored the
329 sequential accumulation of LOH events of these two driver mutations (Fig 3D). For
330 example, the *TP53* mutation clearly occurred before the 17p copy neutral loss of
331 heterozygosity (CN-LOH), as it was present on both copies of chromosome 17p.
332 Although it's hard to infer the exact order of *CDK12* mutation and one copy loss of
333 chromosome 17q11.2-21.2 by existing algorithms, the conclusion of *CDK12* and

334 *TP53* mutation occurred before tumor clonal expansions could be drawn.

335 Next we determined the clonal relationship between tumor cell subpopulations. We
336 calculated the cancer cell fractions (CCF) of mutations between pairs of samples,
337 and constructed the clonal evolution tree based on somatic mutations using the
338 previously published methods (Fig 3E, F). We identified subclonal mutations
339 private to each of the three primary tumors, all were seeded directly from the most
340 recent common ancestor (MRCA) harboring the *TP53* and *CDK12* alterations. If we
341 used the number of mutations in the corresponding subclones to represent branch
342 lengths in the evolution tree, we found that subclone of the PB3 tumor acquired
343 significantly more mutations than PB1 and PB2 (Fig 3A, F). However, examining
344 the mutational signature of PB3 did not reveal meaningful interpretations for this
345 anomaly (Supplementary Fig 3). Manual review of these mutations confirmed that
346 they are true positive mutations for PB3, and not false negatives for PB1 or PB2.
347 This result highlights the intratumoral heterogeneity of primary prostate tumor.
348 Overall, we observed inactivation events of *TP53* and *CDK12* genes in early tumor
349 evolution stage, suggesting that they are driver events for the origin of prostate
350 cancer in this patient.

351 **Intratumoral genetic heterogeneity of prostate metastatic tumors**

352 Warm autopsy could provide an invaluable resource to determine the
353 mutational landscape and cancer evolution from localized tumor to metastatic
354 tumors, and to reveal potential treatment targets. To understand the genomic

355 intratumoral heterogeneity, we applied stringent alterations calling pipelines
356 including somatic mutations and copy number alterations (CNAs) using WGS
357 data from all sequenced samples (Fig 2D). In total, an average of 96 (25–238)
358 and 57 (41–120) nonsynonymous mutations were detected in primary and
359 metastatic tumors, respectively (Fig 4A). At the CNA level, an average of 98
360 (31–213) gains or amplifications, 38 (8–68) losses or deletions and 23 (8–62)
361 CN-LOHs were detected. The average tumor purities of all samples were 0.60
362 (0.34-0.78) as estimated by FACETS¹⁸. We defined the driver events (Fig 4B,
363 Supplementary Table S3) for each tumor using previously established
364 methods¹⁹. In addition to the clonal mutations in *CDK12* and *TP53*,
365 amplification of the *AR* gene was observed in all metastatic samples which
366 could contribute to castration resistance (Fig 4B). Intriguingly, a truncating
367 mutation of *CDKN1B* p.(Gly97Valfs*22) private to all metastases except for
368 bone sample (LV2M) was identified and validated (Supplementary Fig 4). These
369 findings suggested that the truncated *CDKN1B* may be a potential driver for
370 tumor lymphatic metastases and periprostatic organ invasion. We also
371 conducted preliminary data analysis and experimental verification in the
372 subsequent section.

373 To infer the clonal architecture in tumor metastasis, we utilized mutation and
374 CNA information from WES data which had higher depth to perform clonal
375 evolution analysis. We selected 285 somatic mutations detected by both WGS

376 and WES (except for LV2M) as input to PyClone²⁰ and identified 11 major
377 clusters by calculating the CCF and clustering (Supplementary Fig 5). The
378 clonal ordering and a phylogenetic tree were constructed by ClonEvol²¹, which
379 determined the clonal relationship among tumors (Fig 4C). We observed the
380 tumor metastasis underwent approximately three processes that are distinctly
381 histologically characterized. The tumor was first metastasized to the bone
382 (LV2M), and then spread to the lymph nodes (SCLN, RMLN, and MSLN) in turn
383 after acquiring the metastatic dominant mutation of *CDKN1B*, and finally
384 invaded the adjacent organs of the prostate (PMI, BDI, and SVI). The “body
385 maps” were created to characterize the order of driver events and movement of
386 subclones from primary tumor to metastasis (Fig 4D). Metastasis to bone was
387 directly seeded by MRCA, suggesting that LV2M may appear early in systemic
388 disease with a distinct pathway from other metastases.

389 To summarize, from a genetic and molecular perspective, tumor metastases in this
390 case was primarily driven by *CDKN1B* mutations, but bone metastasis was
391 characterized by an entirely different evolutionary process harboring *FUS*
392 mutation.

393 ***CDKN1B* alterations in prostate cancer metastasis**

394 To delineate the genomic alteration atlas of *CDKN1B* in prostate cancer, we
395 preliminarily checked alterations of *CDKN1B* in prostate cancer cohorts from
396 Cbioportal (<https://www.cbioportal.org/>). Among a total of 9510 prostate cancer

397 patients, approximately 4% exhibited variations in the *CDKN1B* gene, which
398 were predominantly truncated mutations and deep deletions ([Supplementary](#)
399 [Fig 6A](#)). We checked the mutational spectrum, and found the *CDKN1B* mutation
400 p.(Gly97Valfs*22) detected in this case were also identified by the metastatic
401 prostate cancer cohort MSK³² ([Fig 5A](#)). Importantly, we observed the mutation
402 was located within a hot spot (amino acids 83-102), which specifically enriched
403 in the metastatic patients. Even though we did not obtain statistically significant
404 results, these findings still indicated that hot spot mutations represented by
405 p.(Gly97Valfs*22) may be driver events leading to prostate cancer metastasis.
406 Furthermore, using RNA-seq data from this warm autopsy patient and
407 previously published CPGEA cohort¹⁵, we found that the RNA expression of
408 *CDKN1B* was down-regulated in metastases (truncating) compared with
409 primary tumor samples ([Supplementary Fig 6B](#)). The pattern was further
410 validated by using TCGA public data³³ ([Supplementary Fig 6C](#)). These results
411 implied that the genomic variations (truncating or deletion) of *CDKN1B* could
412 lead to down-regulation of expression and promote the metastasis of prostate
413 cancer.

414 To explore the function of the down-regulation of *CDKN1B* expression, we
415 designed and synthesized two sets of shRNA sequences and one set of control
416 shRNA sequences. The cell line 22RV1 was chosen in all subsequent
417 experiments due to the highest expression of *CDKN1B* ([Supplementary Fig 7](#))

418 and originating from primary prostate cancer. We observed that the migration
419 and invasion abilities in the *CDKN1B* downexpression group was significantly
420 increased when compared with the control group (Fig 5B, C and D,
421 Supplementary Fig 7). Taken together, the results suggested that the
422 down-regulation of *CDKN1B* may be involved in metastasis of prostate cancer.

423 **Intratumor heterogeneity of DNA methylation and epigenomic evolution**

424 Our previous study demonstrated the congruence of genomic and epigenomic
425 tumor evolutionary histories in a large population¹⁵. To comprehensively dissect
426 the epigenetic clonal evolution of tumor metastases, we applied genome-wide
427 DNA methylation analysis from seven metastatic samples in this case (Fig 2D).
428 The WGBS data of three normal prostate specimens from a previous study³⁴ were
429 used as the reference prostate epigenome in this analysis (Supplementary Fig 8A,
430 B). By using the 1% of CpG sites with the greatest intratumoral methylation
431 variation for unsupervised clustering analysis, we observed the overall
432 hypomethylation patterns in tumor samples and the extensive epigenetic
433 heterogeneity across anatomically distinct metastasis samples (Fig 6A). To define
434 the signatures of DNA methylation heterogeneity, we examined the genomic
435 context of the CpG sites with the most variable methylation levels across samples.
436 The variable sites within tumors were not distributed evenly across the genome,
437 but were enriched in CpG islands and promoters, which showed greater
438 intratumoral heterogeneity than other genomic features examined (Fig 6B).

439 The highly dynamic genetic alterations and the extensive epigenetic heterogeneity
440 across metastases prompted us to investigate the association between genetics
441 and epigenetics during tumor evolution. We constructed a phylogenetic tree based
442 on DNA methylation levels across samples²⁴. The epigenetic phylogenetic tree
443 almost superimposed the genetic tree constructed based on genetic mutation data
444 in their topology (Fig 6C, Fig 4C, Supplementary Fig 8D). To quantify the
445 resemblance between somatic mutation and DNA methylation based phylogenetic
446 trees, we used variant allele fraction and cancer cell fraction to calculate the
447 Euclidean distance and constructed the genetic evolution trees, respectively (Fig
448 6D). In addition to CCF showing a phylogenetic relationship almost consistent with
449 methylation, we also confirmed the congruence between epigenetic and genetic
450 evolution by calculating the Spearman correlation coefficient for distance matrices
451 (Fig 6E). Finally, we defined the hyper- and hypo-methylation of CpG island in
452 promoter region of known prostate cancer driver genes, and investigated which
453 genes were affected by methylation events (Fig 6F, Supplementary Fig 8C). We
454 observed that some genes that have been verified to be frequently altered in DNA
455 methylation in prostate cancer, such as *GSTP1*, *AOX1* and *CCDC68*^{15,35,36}, were
456 hypermethylated in all metastases in this patient, indicating that they were likely
457 clonal events and may occur earlier in prostate cancer evolution. Together, we
458 showed the extensive epigenetic heterogeneity across prostate cancer metastases,

459 which displayed a phylogenetic relationship recapitulating the genetic clonal
460 evolution.

461 **Discussion**

462 The development of warm autopsy program empowered the investigators with the
463 unprecedented ability to thoroughly sampling and comprehensively dissect the
464 evolutionary trajectories of metastatic-lethal prostate cancer^{7,22,37,38}. Warm autopsy
465 program now has been implemented in various types of research facilities:
466 non-profit research institutes, universities and federal research institutes in
467 America^{7,10}, Spain³⁹, England⁴⁰, Australia⁴¹, etc. However, protocols and
468 guidelines for warm autopsy have been individually modified according to the
469 policies of different countries, such as ethics⁹, standard operation procedures⁸ and
470 difficulties in practice^{5,10}.

471 Despite the potential benefits of warm autopsy, the barriers and restrictions in
472 implementation and development have limited the number of autopsies in cancer
473 patients, especially in China⁴². Due to the traditional concept of preserving the
474 intact body after death, the development of the body donation and autopsy system
475 in China has been relatively slow⁴³. The societal and community resistance are
476 generally derived from concerns regarding body disfigurement after the autopsy,
477 unwillingness from the patient's families, and a lack of awareness towards the
478 practice of autopsy. The logistical challenges not only require researchers to build
479 a multi-departmental team, but also to have access to round-the-clock services for

480 preservation of tissue integrity⁴⁴. Additional consideration includes legal
481 requirements and ethics guidelines governing consent for autopsy procedures,
482 and the lack of awareness of warm autopsy among academic oncologists or
483 investigators⁴⁵.

484 In this study, we performed, to our knowledge, the first warm autopsy program in
485 China. Through multidisciplinary teamwork, we collected eight metastatic tissues
486 from a mCRPC patient throughout the warm autopsy within 2.5 hours after death.

487 We comprehensively depicted the genetic and epigenetic cancer clonal evolution,
488 and dissected the heterogeneous dynamics of the metastatic process of prostate

489 cancer in this patient. Furthermore, we found that there was a hot spot in *CDKN1B*,
490 which may be an important driver event to promote prostate cancer metastasis.

491 The protein p27Kip1, encoded by *CDKN1B*, could inhibit tumor cell migration and
492 invasion by binding to stathmin⁴⁶. When *CDKN1B* was truncated, the loss of

493 stathmin binding region (amino acids 170-198) and downregulation of expression
494 may be the mechanism that promotes tumor metastasis⁴⁷. In prostate cancer, the

495 predominant variant types of *CDKN1B* were truncating mutation and deep deletion,
496 which have been associated with increased risks of metastasis^{48,49}. Finally, the

497 metastatic phylogenetic tree we constructed further supported the previous
498 viewpoint that genetics and epigenetics are concordant in tumor evolution^{24,50,51}.

499 The Changhai Warm Autopsy Team (CWAT) was dedicated to collect samples
500 from end-stage disease and identify resistant and metastatic mechanisms of

501 cancer. With the support of CWAT, here, we not only performed warm autopsy, but
502 also explored and established the internationally accepted standards in cancer
503 field in China. This study and the warm autopsy program have important clinical
504 and research implications. Our previous work in building the Chinese Prostate
505 Cancer Genome and Epigenome Atlas revealed genomic and epigenomic
506 signatures that were distinct from those of Western patients^{15,33}. Investigating how
507 such signatures evolve during tumorigenesis and metastasis can be critical to the
508 understanding of disease mechanism and development of therapy. Warm autopsy
509 provides an important platform to collect appropriate specimens for achieving the
510 goal of reconstructing the steps of tumour evolution from initiation to metastasis⁵².
511 Moving forward, we will initiate warm autopsy programs in large cohorts, conduct
512 no fewer than 10 warm autopsies per year. Meanwhile, we are designing clinical
513 trials to integrate longitudinal genomic and epigenomic studies to track cancer
514 resistance and dissemination, following the TRACERx Consortium model^{53,54}.
515 Furthermore, we have initiated programs to raise awareness of warm autopsy
516 among patients, their relatives, and the general public.

517 **Conclusions**

518 We performed the first warm autopsy in China. We call on Chinese urologists and
519 oncologists to promote warm autopsy of prostate cancer. We found the driver gene
520 *CDKN1B* that is associated with the metastasis of prostate cancer, and the
521 mechanism of this gene's role in metastasis awaits further investigation. We also

522 delineated the congruence of genetic and epigenetic clonal evolution during tumor
523 metastasis. In conclusion, the warm autopsy process and standard and analysis
524 pipelines we have established will pave the way for more investigators to apply
525 them to the clinical diagnosis and treatment of prostate cancer.

526 **Data availability**

527 The sequencing data in BAM format are available at the Genome Sequence
528 Archive (GSA) for Human at the BIG Data Center
529 (<http://bigd.big.ac.cn/gsa-human/>), Beijing Institute of Genomics with the
530 accession number PRJCA010385.

531 **Acknowledgements**

532 We sincerely thank the patient and his family. We wish to expressly thank
533 Zhengmao Lu (Department of General Surgery), Changwei Yang (Department of
534 Orthopaedic Surgery), Yuan Zou (Department of Neurosurgery), Chenguang Li
535 (Department of Cardiothoracic Surgery) and Yeqing Lu (Operating Room) for the
536 critical help implementing the warm autopsy. We would like to thank Guiling Ding
537 (Department of Pathology) and Cong Wu (Biological Sample Bank) for
538 coordinating the pathology review, tissue processing and labeling.

539 **Funding information**

540 This work was supported by the Promote Clinical Skills and Innovation Ability of
541 Municipal Hospitals Project (SHDC2020CR6007), Shanghai Rising-Star Program
542 (20QA1411800) and National Natural Science Foundation of China (82022055).

543 **Authors' contributions**

544 Conceptualization, XG and JL; Formal Analysis, WZ, TW and ZW; Investigation,
545 BL, LC and XY; Writing—Original Draft, WZ and HS; Writing—Review & Editing,
546 YW, MQ and XL; Funding Acquisition, XG and JL; Resources, YY, QY and FL;
547 Supervision, ZL. All authors read and approved the final manuscript.

548 **Ethics approval and consent to participate**

549 This study was approved by the ethical board at Changhai Hospital (No:
550 TMEC2014-001, No: CHEC2019-165). Informed consent was obtained from all
551 participants involved in the study, and all experiments were conducted in line with
552 the principles of the Declaration of Helsinki.

553 **Consent for publication**

554 There are no individual person's data from all participants involved in the study.

555 **Conflict of interest**

556 The authors declare that they have no competing interests.

557

558 References

- 559 1 Kimura, T. East meets West: ethnic differences in prostate cancer epidemiology between
560 East Asians and Caucasians. *Chin J Cancer* **31**, 421-429, doi:10.5732/cjc.011.10324
561 (2012).
- 562 2 Bubendorf, L. *et al.* Metastatic patterns of prostate cancer: an autopsy study of 1,589
563 patients. *Hum Pathol* **31**, 578-583, doi:10.1053/hp.2000.6698 (2000).
- 564 3 Roudier, M. P. *et al.* Histopathological assessment of prostate cancer bone osteoblastic
565 metastases. *J Urol* **180**, 1154-1160, doi:10.1016/j.juro.2008.04.140 (2008).
- 566 4 Harris, C. C. *et al.* Binding of (3H)benzo(a)pyrene to DNA in cultured human bronchus.
567 *Cancer Res* **36**, 1011-1018 (1976).
- 568 5 Lindell, K. O., Erlen, J. A. & Kaminski, N. Lessons from our patients: development of a
569 warm autopsy program. *PLoS Med* **3**, e234, doi:10.1371/journal.pmed.0030234 (2006).
- 570 6 Bidaut-Russell, M., Dowd, D. M., Grossberg, G. T. & Zimny, G. H. Survey of U.S. Alzheimer
571 Brain Banks: a 1990 directory. *Alzheimer Dis Assoc Disord* **5**, 188-193 (1991).
- 572 7 Rubin, M. A. *et al.* Rapid ("warm") autopsy study for procurement of metastatic prostate
573 cancer. *Clin Cancer Res* **6**, 1038-1045 (2000).
- 574 8 Carithers, L. J. *et al.* A Novel Approach to High-Quality Postmortem Tissue Procurement:
575 The GTEx Project. *Biopreserv Biobank* **13**, 311-319, doi:10.1089/bio.2015.0032 (2015).
- 576 9 Pentz, R. D. *et al.* Ethics guidelines for research with the recently dead. *Nat Med* **11**,
577 1145-1149, doi:10.1038/nm1105-1145 (2005).
- 578 10 Shah, R. B. *et al.* Androgen-independent prostate cancer is a heterogeneous group of
579 diseases: lessons from a rapid autopsy program. *Cancer Res* **64**, 9209-9216,
580 doi:10.1158/0008-5472.CAN-04-2442 (2004).
- 581 11 Carithers, L. J. & Moore, H. M. The Genotype-Tissue Expression (GTEx) Project.
582 *Biopreserv Biobank* **13**, 307-308, doi:10.1089/bio.2015.29031.hmm (2015).
- 583 12 Heidenreich, A. *et al.* EAU guidelines on prostate cancer. Part II: Treatment of advanced,
584 relapsing, and castration-resistant prostate cancer. *Eur Urol* **65**, 467-479,
585 doi:10.1016/j.eururo.2013.11.002 (2014).
- 586 13 Kim, S. *et al.* Strelka2: fast and accurate calling of germline and somatic variants. *Nat*
587 *Methods* **15**, 591-594, doi:10.1038/s41592-018-0051-x (2018).
- 588 14 Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants
589 from high-throughput sequencing data. *Nucleic Acids Res* **38**, e164,
590 doi:10.1093/nar/gkq603 (2010).
- 591 15 Li, J. *et al.* A genomic and epigenomic atlas of prostate cancer in Asian populations. *Nature*
592 **580**, 93-99, doi:10.1038/s41586-020-2135-x (2020).
- 593 16 Lawrence, M. S. *et al.* Mutational heterogeneity in cancer and the search for new
594 cancer-associated genes. *Nature* **499**, 214-218, doi:10.1038/nature12213 (2013).
- 595 17 Lefter, M. *et al.* Mutalyzer 2: next generation HGVS nomenclature checker. *Bioinformatics*
596 **37**, 2811-2817, doi:10.1093/bioinformatics/btab051 (2021).

- 597 18 Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity
598 analysis tool for high-throughput DNA sequencing. *Nucleic Acids Res* **44**, e131,
599 doi:10.1093/nar/gkw520 (2016).
- 600 19 Zhang, W. *et al.* Intratumor heterogeneity and clonal evolution revealed in
601 castration-resistant prostate cancer by longitudinal genomic analysis. *Transl Oncol* **16**,
602 101311, doi:10.1016/j.tranon.2021.101311 (2022).
- 603 20 Roth, A. *et al.* PyClone: statistical inference of clonal population structure in cancer. *Nat*
604 *Methods* **11**, 396-398, doi:10.1038/nmeth.2883 (2014).
- 605 21 Dang, H. X. *et al.* ClonEvol: clonal ordering and visualization in cancer sequencing. *Ann*
606 *Oncol* **28**, 3076-3082, doi:10.1093/annonc/mdx517 (2017).
- 607 22 Gundem, G. *et al.* The evolutionary history of lethal metastatic prostate cancer. *Nature* **520**,
608 353-357, doi:10.1038/nature14347 (2015).
- 609 23 Akalin, A. *et al.* methylKit: a comprehensive R package for the analysis of genome-wide
610 DNA methylation profiles. *Genome Biol* **13**, R87, doi:10.1186/gb-2012-13-10-r87 (2012).
- 611 24 Brocks, D. *et al.* Intratumor DNA methylation heterogeneity reflects clonal evolution in
612 aggressive prostate cancer. *Cell Rep* **8**, 798-806, doi:10.1016/j.celrep.2014.06.053 (2014).
- 613 25 Desper, R. & Gascuel, O. Fast and accurate phylogeny reconstruction algorithms based on
614 the minimum-evolution principle. *J Comput Biol* **9**, 687-705,
615 doi:10.1089/106652702761034136 (2002).
- 616 26 Sun, X. G. H. W. Y. W. C. X. Y. Construction and clinical application of prostate cancer
617 database (PC-Follow) based on browser/server schema. *Chinese Journal of Urology* **36**,
618 694-698 (2015).
- 619 27 Gandaglia, G. *et al.* Distribution of metastatic sites in patients with prostate cancer: A
620 population-based analysis. *Prostate* **74**, 210-216, doi:10.1002/pros.22742 (2014).
- 621 28 Gandaglia, G. *et al.* Impact of the Site of Metastases on Survival in Patients with Metastatic
622 Prostate Cancer. *Eur Urol* **68**, 325-334, doi:10.1016/j.eururo.2014.07.020 (2015).
- 623 29 Quigley, D. A. *et al.* Genomic Hallmarks and Structural Variation in Metastatic Prostate
624 Cancer. *Cell* **174**, 758-769 e759, doi:10.1016/j.cell.2018.06.039 (2018).
- 625 30 Reimers, M. A. *et al.* Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced
626 Prostate Cancer. *Eur Urol* **77**, 333-341, doi:10.1016/j.eururo.2019.09.036 (2020).
- 627 31 Yang, L. *et al.* An enhanced genetic model of colorectal cancer progression history.
628 *Genome Biol* **20**, 168, doi:10.1186/s13059-019-1782-4 (2019).
- 629 32 Stopsack, K. H. *et al.* Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes
630 in Metastatic Castration-Sensitive Prostate Cancer. *Clin Cancer Res* **26**, 3230-3238,
631 doi:10.1158/1078-0432.CCR-20-0168 (2020).
- 632 33 Cancer Genome Atlas Research, N. The Molecular Taxonomy of Primary Prostate Cancer.
633 *Cell* **163**, 1011-1025, doi:10.1016/j.cell.2015.10.025 (2015).
- 634 34 Wang, T. *et al.* Integrative Epigenome Map of the Normal Human Prostate Provides
635 Insights Into Prostate Cancer Predisposition. *Front Cell Dev Biol* **9**, 723676,
636 doi:10.3389/fcell.2021.723676 (2021).

- 637 35 Henrique, R. & Jeronimo, C. Molecular detection of prostate cancer: a role for GSTP1
638 hypermethylation. *Eur Urol* **46**, 660-669; discussion 669, doi:10.1016/j.eururo.2004.06.014
639 (2004).
- 640 36 Li, W. *et al.* Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. *Eur*
641 *Urol* **74**, 710-719, doi:10.1016/j.eururo.2018.06.021 (2018).
- 642 37 Haffner, M. C. *et al.* Tracking the clonal origin of lethal prostate cancer. *J Clin Invest* **123**,
643 4918-4922, doi:10.1172/JCI70354 (2013).
- 644 38 Grasso, C. S. *et al.* The mutational landscape of lethal castration-resistant prostate cancer.
645 *Nature* **487**, 239-243, doi:10.1038/nature11125 (2012).
- 646 39 Xie, T. *et al.* Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models
647 Reveals Possible Driver Mutations Underlying Tumor Progression. *PLoS One* **10**,
648 e0142631, doi:10.1371/journal.pone.0142631 (2015).
- 649 40 (<https://ClinicalTrials.gov/show/NCT03004755>, 2016).
- 650 41 Alsop, K. *et al.* A community-based model of rapid autopsy in end-stage cancer patients.
651 *Nat Biotechnol* **34**, 1010-1014, doi:10.1038/nbt.3674 (2016).
- 652 42 Zhu, M. H. & Yu, D. H. Fluctuations in the rate of autopsy in China. *Chin Med J (Engl)* **124**,
653 3403-3407 (2011).
- 654 43 Zheng, W. Q., Fan, Y. H. & Ng, A. Public attitudes towards the autopsy in China. *Pathology*
655 **30**, 92-94 (1998).
- 656 44 Savas, P. *et al.* The Subclonal Architecture of Metastatic Breast Cancer: Results from a
657 Prospective Community-Based Rapid Autopsy Program "CASCADE". *PLoS Med* **13**,
658 e1002204, doi:10.1371/journal.pmed.1002204 (2016).
- 659 45 Krook, M. A., Chen, H. Z., Bonneville, R., Allenby, P. & Roychowdhury, S. Rapid Research
660 Autopsy: Piecing the Puzzle of Tumor Heterogeneity. *Trends Cancer* **5**, 1-5,
661 doi:10.1016/j.trecan.2018.11.004 (2019).
- 662 46 Baldassarre, G. *et al.* p27(Kip1)-stathmin interaction influences sarcoma cell migration and
663 invasion. *Cancer Cell* **7**, 51-63, doi:10.1016/j.ccr.2004.11.025 (2005).
- 664 47 Cusan, M. *et al.* Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other
665 Hormone-Driven Human Tumors. *Front Endocrinol (Lausanne)* **9**, 393,
666 doi:10.3389/fendo.2018.00393 (2018).
- 667 48 Faisal, F. A. *et al.* CDKN1B Deletions are Associated with Metastasis in African American
668 Men with Clinically Localized, Surgically Treated Prostate Cancer. *Clin Cancer Res* **26**,
669 2595-2602, doi:10.1158/1078-0432.CCR-19-1669 (2020).
- 670 49 Macri, E. & Loda, M. Role of p27 in prostate carcinogenesis. *Cancer Metastasis Rev* **17**,
671 337-344, doi:10.1023/a:1006133620914 (1998).
- 672 50 Zhu, B. *et al.* The genomic and epigenomic evolutionary history of papillary renal cell
673 carcinomas. *Nat Commun* **11**, 3096, doi:10.1038/s41467-020-16546-5 (2020).
- 674 51 Mazor, T. *et al.* DNA Methylation and Somatic Mutations Converge on the Cell Cycle and
675 Define Similar Evolutionary Histories in Brain Tumors. *Cancer Cell* **28**, 307-317,
676 doi:10.1016/j.ccell.2015.07.012 (2015).

- 677 52 Hessey, S., Fessas, P., Zaccaria, S., Jamal-Hanjani, M. & Swanton, C. Insights into the
678 metastatic cascade through research autopsies. *Trends Cancer*,
679 doi:10.1016/j.trecan.2023.03.002 (2023).
680 53 Bailey, C. *et al.* Tracking Cancer Evolution through the Disease Course. *Cancer Discov* **11**,
681 916-932, doi:10.1158/2159-8290.CD-20-1559 (2021).
682 54 Jamal-Hanjani, M. *et al.* Tracking the Evolution of Non-Small-Cell Lung Cancer. *N Engl J*
683 *Med* **376**, 2109-2121, doi:10.1056/NEJMoa1616288 (2017).
684

685 **Figure Legend**

686 **Fig. 1 Workflow diagram giving overview of warm autopsy.**

687 The four steps of the study are shown on the left. The right shows in detail the
688 organization of the warm autopsy committee, as well as the operating table layout
689 in implementation.

690 **Fig. 2 Clinical course and serial procurement of the patient.**

691 (A) The clinical course of disease progression and treatment in this index case.
692 The bottom figure shows the pathology of biopsies (200x magnification). (B) The
693 pathology of metastatic sites procured by warm autopsy (200x magnification). All
694 the hematoxylin and eosin (H&E) stains were performed using standard
695 techniques. (C) Tissue and blood samples taken at different times. Two lymph
696 node metastases samples taken on day 210 were not sequenced. R, right; L, left;
697 LN, lymph node. (D) The type of sequencing performed. The abbreviations of
698 samples are indicated. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedding.

699 **Fig. 3 Intratumoral genetic heterogeneity of prostate primary tumors.**

700 (A) The regional distribution of nonsynonymous mutations in primary tumors. The
701 heat map indicates the presence of a mutation (purple) or its absence (white) in the

702 individual tumor. Right showed the gene names of driver mutations. The *TP53*
703 mutation was not detected in the PB2 sample using WGS due to insufficient total
704 depth, and the number in square indicate the alt_reads/total_reads/allele_fraction.
705 (B) The figure shows the allele fraction distributions plotted by mutation number
706 (left vertical axis) and density (right vertical axis). Tumor purity provided by
707 FACETS in three samples is also indicated. (C) Copy number profile of chr17 and
708 the LOH of *TP53* and *CDK12*. Shown from upper to lower are the total copy
709 number log-ratio (the log ratio of total read depth in the tumor versus that in the
710 normal), allele-specific log-odds-ratio (the log odds ratio of the variant allele count
711 in the tumor versus in the normal), and corresponding integer (total, minor) copy
712 number calls provided by FACETS. (D) The figure demonstrates how somatic
713 mutations accumulate in a CN-LOH (*TP53*) and Loss (*CDK12*) chromosome. (E)
714 Cancer cell fractions and clusters of mutations inferred by PyClone for pairs of
715 samples. Blue density areas reveal the mutation clusters present at clonal or
716 subclonal levels, and the manually colored circles provide the localization of
717 mutation clusters in different samples. Driver mutation genes present in the cluster
718 are marked in red. (F) The clonal evolution tree of the primary tumor. The length of
719 branches connecting clones is proportional to the number of mutations contained,
720 and the driver events identified are marked on the tree.

721 **Fig 4. Intratumoral genetic heterogeneity and clonal evolution of prostate**
722 **metastatic tumors.**

723 (A) An overview of somatic alterations detected in 11 tumors. Each panel displays
724 the number of mutations in coding region, nonsynonymous mutations, the number
725 of segments for copy number alterations, and the tumor purity, respectively. (B)
726 Overview of the analyzed driver genomic alterations in the primary tumor and
727 metastases. (C) The clonal evolution tree of the primary tumor and metastases
728 inferred by ClonEvol. Except for cluster 12 private to LV2M, which is manually
729 added, all the CCF clusters were calculated by PyClone. The branch length is
730 scaled by the log₂ ratio of the number of mutations in the individual clone. The
731 potential driver events are highlighted. (D) The emergence and movement of
732 clones in the spread of metastasis. The color-coded arrows depict the seeding
733 events and the acquisition of mutations, and the sequence of events is ordered
734 according to the clonal evolution relationship. Plus (+), the acquisition of subclone.

735 **Fig 5. *CDKN1B* alterations in prostate cancer metastasis.**

736 (A) The position distribution of *CDKN1B* somatic mutations in this patient and in
737 the deduplicated samples from cbioprotal. The circles are colored with respect to
738 the different mutation types, and the size represents the number of patients with
739 the mutation. (B) Scratch assay of 22RV1 cells transfected with shRNA (n = 3),
740 which corresponds to Supplementary Fig 7D. (C, D) Images of migrating and
741 invading cells tested by using Transwell assays for 22RV1 cells transfected with
742 shRNA (n = 3). *P* values were determined by two-tailed Student's *t* test.

743 **Fig 6. Intratumor heterogeneity of DNA methylation and epigenomic**

744 **evolution in prostate metastatic tumors.**

745 (A) The figure shows the intratumoral heterogeneity of methylation patterns
746 depicted by unsupervised hierarchical clustering using the top 1% of CpG sites (n
747 = 150,000) with the greatest difference. Normal samples were excluded for the
748 hierarchical clustering but were input into row clustering. (B) DNA methylation
749 Intratumor heterogeneity on genomic regions. The median methylation variability
750 on the right of the figure was calculated by the range of CpG sites (maximum level
751 - minimal level) between tumors. (C) Epigenomic clonal evolution tree inferred from
752 DNA methylation distance matrices. Lengths of trunks and branches were inferred
753 using the top 1% of CpG sites (same as Fig 5A, see Supplemental Methods). Color
754 coding is the same as in Fig 4F. (D) Genomic clonal evolution tree inferred from
755 CCF (cancer cell fraction, left) and VAF (variant allele fraction, right) distance
756 matrices. (E) The correlation between epigenomic distance matrices and genomic
757 distance matrices (CCF, left; VAF, right). LOESS fitted curve and 95% confident
758 interval are presented. Rho coefficient (R) and P value (P) are assessed by
759 Spearman's rank correlation. (F) The difference in methylation levels of CpG island
760 in promoter region of known prostate cancer driver genes
761 (www.genome.jp/pathway/ko05215) between each tumor and three normal
762 prostate samples. Hyper-methylation and hypo-methylation were defined as
763 difference of more than 20%. White cells in the heatmap represent differences
764 below 20%.






Fig. 1 Workflow diagram giving overview of warm autopsy.

The four steps of the study are shown on the left. The right shows in detail the organization of the warm autopsy committee, as well as the operating table layout in implementation.


A



B



C



D

	WGS	WES	WGBS	RNA	
Biopsy	PB1				■ Primary ■ FFPE
	PB2				■ Primary ■ FFPE
	PB3				■ Primary ■ FFPE
	PBN				■ Normal ■ FFPE
Warm Autopsy	SVI				■ Metastasis ■ Fresh-Frozen
	BDI				■ Metastasis ■ Fresh-Frozen
	PMI				■ Metastasis ■ Fresh-Frozen
	PVLN				■ Metastasis ■ Fresh-Frozen
	RMLN				■ Metastasis ■ Fresh-Frozen
	MSLN				■ Metastasis ■ Fresh-Frozen
	SCLN				■ Metastasis ■ Fresh-Frozen
	LV2M				■ Metastasis ■ Fresh-Frozen

■ Metastasis ■ Primary ■ Normal
 ■ Fresh-Frozen ■ FFPE

SVI: Seminal Vesicle (Invasion)
 BDI: Bladder (Invasion)
 PMI: Peritoneum (Invasion)
 PVLN: Pelvic Lymph Node (Metastases)
 RMLN: Retroperitoneal Lymph Node (Metastases)
 MSLN: Mesenteric Lymph Node (Metastases)
 SCLN: Supraclavicular Lymph Node (Metastases)
 LV2M: Second Lumbar Vertebra (Metastases)

Fig. 2 Clinical course and serial procurement of the patient.

(A) The clinical course of disease progression and treatment in this index case. The bottom figure shows the pathology of biopsies (200x magnification). (B) The pathology of metastatic sites procured by warm autopsy (200x magnification). All the hematoxylin and eosin (H&E) stains were performed using standard techniques. (C) Tissue and blood samples taken at different times. Two lymph node metastases samples taken on day 210 were not sequenced. R, right; L, left; LN, lymph node. (D) The type of sequencing performed. The abbreviations of samples are indicated. FF, fresh frozen; FFPE, formalin-fixed paraffin-embedding.




Fig. 3 Intratumoral genetic heterogeneity of prostate primary tumors.

(A) The regional distribution of nonsynonymous mutations in primary tumors. The heat map indicates the presence of a mutation (purple) or its absence (white) in the individual tumor. Right showed the gene names of driver mutations. The *TP53* mutation was not detected in the PB2 sample using WGS due to insufficient total depth, and the number in square indicate the alt_reads/total_reads/allele_fraction. (B) The figure shows the allele fraction distributions plotted by mutation number (left vertical axis) and density (right vertical axis). Tumor purity provided by FACETS in three samples is also indicated. (C) Copy number profile of chr17 and the LOH of *TP53* and *CDK12*. Shown from upper to lower are the total copy number log-ratio (the log ratio of total read depth in the tumor versus that in the normal), allele-specific log-odds-ratio (the log odds ratio of the variant allele count in the tumor versus in the normal), and corresponding integer (total, minor) copy number calls provided by FACETS. (D) The figure demonstrates how somatic mutations accumulate in a CN-LOH (*TP53*) and Loss (*CDK12*) chromosome. (E) Cancer cell fractions and clusters of mutations inferred by PyClone for pairs of samples. Blue density areas reveal the mutation clusters present at clonal or subclonal levels, and the manually colored circles provide the localization of mutation clusters in different samples. Driver mutation genes present in the cluster are marked in red. (F) The clonal evolution tree of the primary tumor. The length of branches connecting clones is proportional to the number of mutations contained, and the driver events identified are marked on the tree.




Fig 4. Intratumoral genetic heterogeneity and clonal evolution of prostate metastatic tumors.

(A) An overview of somatic alterations detected in 11 tumors. Each panel displays the number of mutations in coding region, nonsynonymous mutations, the number of segments for copy number alterations, and the tumor purity, respectively. (B) Overview of the analyzed driver genomic alterations in the primary tumor and metastases. (C) The clonal evolution tree of the primary tumor and metastases inferred by ClonEvol. Except for cluster 12 private to LV2M, which is manually added, all the CCF clusters were calculated by PyClone. The branch length is scaled by the log₂ ratio of the number of mutations in the individual clone. The potential driver events are highlighted. (D) The emergence and movement of clones in the spread of metastasis. The color-coded arrows depict the seeding events and the acquisition of mutations, and the sequence of events is ordered according to the clonal evolution relationship. Plus (+), the acquisition of subclone.





Fig 5. *CDKN1B* alterations in prostate cancer metastasis.

(A) The position distribution of *CDKN1B* somatic mutations in this patient and in the deduplicated samples from cbioprotal. The circles are colored with respect to the different mutation types, and the size represents the number of patients with the mutation. (B) Scratch assay of 22RV1 cells transfected with shRNA (n = 3), which corresponds to Supplementary Fig 7D. (C, D) Images of migrating and invading cells tested by using Transwell assays for 22RV1 cells transfected with shRNA (n = 3). P values were determined by two-tailed Student's t test.




Fig 6. Intratumor heterogeneity of DNA methylation and epigenomic evolution in prostate metastatic tumors.

(A) The figure shows the intratumoral heterogeneity of methylation patterns depicted by unsupervised hierarchical clustering using the top 1% of CpG sites ($n = 150,000$) with the greatest difference. Normal samples were excluded for the hierarchical clustering but were input into row clustering. (B) DNA methylation intratumor heterogeneity on genomic regions. The median methylation variability on the right of the figure was calculated by the range of CpG sites (maximum level - minimal level) between tumors. (C) Epigenomic clonal evolution tree inferred from DNA methylation distance matrices. Lengths of trunks and branches were inferred using the top 1% of CpG sites (same as Fig 5A, see Supplemental Methods). Color coding is the same as in Fig 4F. (D) Genomic clonal evolution tree inferred from CCF (cancer cell fraction, left) and VAF (variant allele fraction, right) distance matrices. (E) The correlation between epigenomic distance matrices and genomic distance matrices (CCF, left; VAF, right). LOESS fitted curve and 95% confidence interval are presented. Rho coefficient (R) and P value (P) are assessed by Spearman's rank correlation. (F) The difference in methylation levels of CpG island in promoter region of known prostate cancer driver genes (www.genome.jp/pathway/ko05215) between each tumor and three normal prostate samples. Hyper-methylation and hypo-methylation were defined as difference of more than 20%. White cells in the heatmap represent differences below 20%.